Figure 5 - available via license: Creative Commons Attribution 4.0 International
Content may be subject to copyright.
Download
View publication
Binding experiments using as ligands human VEGF-C, human VEGF-D and human VEGF. (a) Binding to VEGF-C or VEGF of different types of samples with specificity for VEGF. Myctagged proteins, VEGF-C or VEGF obtained from CHO cells (hVEGF-C CHO or hVEGF CHO,

Binding experiments using as ligands human VEGF-C, human VEGF-D and human VEGF. (a) Binding to VEGF-C or VEGF of different types of samples with specificity for VEGF. Myctagged proteins, VEGF-C or VEGF obtained from CHO cells (hVEGF-C CHO or hVEGF CHO,

Source publication
Figure 2 Anti-VEGF IgG seroconversion study and serum blocking activity...
Figure 3 VEGF-specific IgG subclasses between weeks 6-12, 16-48, 49-96...
Figure 4 Immunologic properties of the IgG fraction purified from de...
Figure 5 Binding experiments using as ligands human VEGF-C, human...
Patients with different clinical conditions vaccinated with CIGB-247...
Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.
Preprint
Full-text available
  • Jan 2020
Background: CIGB-247 is a cancer therapeutic vaccine that uses as antigen a variant of human vascular endothelial growth factor (VEGF) mixed with the bacterially-derived adjuvant VSSP. CIGB-247 has been already evaluated in two phase I clinical trials (CENTAURO and CENTAURO-2), showing to be safe and immunogenic in advanced cancer patients selected...
Cite
Download full-text

Contexts in source publication

Context 1
... hVEGF-C CHO is captured with a monoclonal antibody specific to myc-tagged proteins, the optical density observed for PCS and NCS was similar and without statistically significant differences (unpaired t test, p=0.4944) (Fig. 5a). However, VEGF-C CHO was recognized by its cognate ...
Context 2
... and VEGFR3. As expected, there was no binding of VEGFR1 and bevacizumab (Figure 5a). To check this form of ligand presentation in ELISA, hVEGF CHO was evaluated in the same ELISA conditions, and VEGF was recognized by PCS with statistically significant differences as compared to NCS (unpaired t test, p=0.0009). ...
Context 3
... form of ligand presentation in ELISA, hVEGF CHO was evaluated in the same ELISA conditions, and VEGF was recognized by PCS with statistically significant differences as compared to NCS (unpaired t test, p=0.0009). Also, VEGF was recognized by bevacizumab and its cognate receptors VEGFR1 and VEGFR2. As expected, there was no binding for VEGFR3 (Fig. ...
Context 4
... CHO was recognized by VEGFR3 when captured through its histidine tag using nickel coated high sensitivity multiwell plates; binding of IgG comp was lower than that observed for IgG neg with statistically significant differences (unpaired t test, p=0.0368) (Fig. 5b). Similar result was obtained for commercially available VEGF-D (unpaired t test, p=0.0061). For commercially available VEGF-C, no differences were found between IgG comp and IgG neg (unpaired t test, p=0.0660). This form of ligand presentation in ELISA was checked using hVEGF CHO at the same conditions. As expected, VEGF was recognized ...
Context 5
... found between IgG comp and IgG neg (unpaired t test, p=0.0660). This form of ligand presentation in ELISA was checked using hVEGF CHO at the same conditions. As expected, VEGF was recognized by IgG comp with statistically significant differences as compared to IgG neg (unpaired t test, p=0.0311).There was no binding of VEGFR3 to the captured VEGF (Fig. ...